Assignee
HANGZHOU INNOGATE PHARMA CO LTD
CN·11 granted patents·6 pending applications·4 citations·filing 2016–2022
Top patents by PatentIndex Score
17 records- 0177US11352353B2Heterocyclic compound serving as FGFR4 inhibitorHANGZHOU INNOGATE PHARMA CO LTD·Filed 2017·Granted Jun 7, 2022·2 cites·14 claims
- 0270US10730887B2Compound containing tricyclic heteroaryl groupHANGZHOU INNOGATE PHARMA CO LTD·Filed 2017·Granted Aug 4, 2020·1 cites·17 claims
- 0368US11225492B2Heterocycles useful as anti-cancer agentsHANGZHOU INNOGATE PHARMA CO LTD·Filed 2016·Granted Jan 18, 2022·1 cites·14 claims
- 0460US2022002318A1Heterocyclic compound as syk inhibitor and/or syk-hdac dual inhibitorHANGZHOU INNOGATE PHARMA CO LTD·Filed 2021·Application pending·0 cites
- 0557US10968234B2Compound containing tricyclic heteroaryl groupHANGZHOU INNOGATE PHARMA CO LTD·Filed 2020·Granted Apr 6, 2021·0 cites·19 claims
- 0653US12358911B2Heterocyclic comipound as CDK-HDAC dual pathway inhibitorHANGZHOU INNOGATE PHARMA CO LTD·Filed 2019·Granted Jul 15, 2025·0 cites·4 claims
- 0753US2025214965A1Compound as kif18a inhibitorHANGZHOU INNOGATE PHARMA CO LTD·Filed 2022·Application pending·0 cites
- 0852US12415797B2Heterocyclic compound as CDK-HDAC double-channel inhibitorHANGZHOU INNOGATE PHARMA CO LTD·Filed 2019·Granted Sep 16, 2025·0 cites·10 claims
- 0951US2024400545A1Compound serving as kat6 inhibitorHANGZHOU INNOGATE PHARMA CO LTD·Filed 2022·Application pending·0 cites
- 1050US2025255868A1Heterocyclic compound acting as kras g12d inhibitorHANGZHOU INNOGATE PHARMA CO LTD·Filed 2022·Application pending·0 cites
- 1149US2022153766A1Condensed tricyclic compound used as kinase inhibitorHANGZHOU INNOGATE PHARMA CO LTD·Filed 2020·Application pending·0 cites
- 1248US12589092B2Polycyclic compound acting as kinase inhibitorHANGZHOU INNOGATE PHARMA CO LTD·Filed 2021·Granted Mar 31, 2026·0 cites·20 claims
- 1348US2024336562A1Compound serving as nlrp3 inhibitorHANGZHOU INNOGATE PHARMA CO LTD·Filed 2022·Application pending·0 cites
- 1447US11142535B2Heterocyclic compound as Syk inhibitor and/or Syk-HDAC dual inhibitorHANGZHOU INNOGATE PHARMA CO LTD·Filed 2017·Granted Oct 12, 2021·0 cites·10 claims
- 1539US11266640B2Polycyclic compound acting as IDO inhibitor and/or IDO-HDAC dual inhibitorHANGZHOU INNOGATE PHARMA CO LTD·Filed 2018·Granted Mar 8, 2022·0 cites·24 claims
- 1636US10934311B2Heterocyclic compound used as FGFR inhibitorHANGZHOU INNOGATE PHARMA CO LTD·Filed 2017·Granted Mar 2, 2021·0 cites·18 claims
- 1735US10358451B2Heterocycles useful as IDO and TDO inhibitorsHANGZHOU INNOGATE PHARMA CO LTD·Filed 2016·Granted Jul 23, 2019·0 cites·26 claims
Join the waitlist — get patent alerts
Get an alert when HANGZHOU INNOGATE PHARMA CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →